Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continu...(ks uncertainties and other factors that ...),Health

Date:11/9/2009

ks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from those referred to or implied in the forward-looking statements. Such risks include, but are not limited to, the risk that Anesiva otherwise fails to comply with the continued listing requirements of The NASDAQ Global Market or any other NASDAQ market; the risk that the parties to the Merger will be unable to satisfy the conditions to closing the Merger or otherwise complete the Merger; the risk of whether certain market segments grow as anticipated; clinical trial results; the competitive environment in the biotechnology industry; and whether the Anesiva can successfully develop new products and the degree to which these gain market acceptance as well as other risks detailed from time to time in Anesiva's filings with the SEC, including Anesiva's most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2008, its Quarterly Reports on Form 10-Q and its Current Reports on Form 8-K as filed with the SEC. Anesiva expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Anesiva's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

SOURCE Anesiva, Inc.

'/>"/>

SOURCE Anesiva, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
2. Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
3. Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company
4. Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery
5. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
6. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
7. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
8. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
9. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
10. Anesiva Defines Regulatory Pathway for Adlea with FDA
11. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery